Stockreport

Prothena’s Partner Roche to Advance Prasinezumab into Phase III Development for Early-Stage Parkinson's Disease

Prothena Corporation plc - Ordinary Shares  (PRTA) 
Last prothena corporation plc - ordinary shares earnings: 2/12 04:05 pm Check Earnings Report
US:NASDAQ Investor Relations: ir.prothena.com
PDF Data from Phase IIb PADOVA study and longer term follow-up data suggest clinical benefit on top of symptomatic treatment in early-stage Parkinson’s diseasePrasinezumab i [Read more]